AR109760A1 - Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson - Google Patents
Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinsonInfo
- Publication number
- AR109760A1 AR109760A1 ARP170102714A ARP170102714A AR109760A1 AR 109760 A1 AR109760 A1 AR 109760A1 AR P170102714 A ARP170102714 A AR P170102714A AR P170102714 A ARP170102714 A AR P170102714A AR 109760 A1 AR109760 A1 AR 109760A1
- Authority
- AR
- Argentina
- Prior art keywords
- tablet
- disease
- parkinson
- methods
- evil
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- MTTHRRVVGMPYQG-ZDUSSCGKSA-N [(1r)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea Chemical compound C([C@H](C1=CC=2)CNC(=O)N)CCC1=CC=2S(=O)(=O)C1=CC=CC(F)=C1 MTTHRRVVGMPYQG-ZDUSSCGKSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402357P | 2016-09-30 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109760A1 true AR109760A1 (es) | 2019-01-23 |
Family
ID=61756894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102714A AR109760A1 (es) | 2016-09-30 | 2017-09-29 | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10314798B2 (https=) |
| EP (1) | EP3518914A4 (https=) |
| JP (1) | JP2019529502A (https=) |
| AR (1) | AR109760A1 (https=) |
| AU (2) | AU2017337053B2 (https=) |
| CA (1) | CA3037059A1 (https=) |
| IL (1) | IL265656A (https=) |
| MX (2) | MX387961B (https=) |
| TW (1) | TWI753952B (https=) |
| WO (1) | WO2018064559A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109760A1 (es) | 2016-09-30 | 2019-01-23 | Biotie Therapies Inc | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson |
| AU2020377451B2 (en) * | 2019-11-04 | 2025-12-04 | Cinclus Pharma Holding AB (publ) | Oral formulation of X842 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039132D1 (de) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-Desmethylvenlafaxin-Succinat |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| MX2007007558A (es) * | 2004-12-21 | 2007-07-24 | Hoffmann La Roche | Derivados de tetralina y de indano y usos de los mismos. |
| CN101472884A (zh) * | 2006-06-20 | 2009-07-01 | 弗·哈夫曼-拉罗切有限公司 | 1,2,3,4-四氢化萘和茚满衍生物及其用途 |
| FR2974102B1 (fr) * | 2011-04-13 | 2014-08-22 | Rhodia Operations | Composition polyamide stabilisee |
| US20150320706A1 (en) * | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| AR109760A1 (es) | 2016-09-30 | 2019-01-23 | Biotie Therapies Inc | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson |
-
2017
- 2017-09-29 AR ARP170102714A patent/AR109760A1/es unknown
- 2017-09-29 US US15/720,947 patent/US10314798B2/en not_active Expired - Fee Related
- 2017-09-29 EP EP17857545.2A patent/EP3518914A4/en not_active Withdrawn
- 2017-09-29 CA CA3037059A patent/CA3037059A1/en not_active Abandoned
- 2017-09-29 MX MX2019003720A patent/MX387961B/es unknown
- 2017-09-29 AU AU2017337053A patent/AU2017337053B2/en not_active Ceased
- 2017-09-29 JP JP2019517827A patent/JP2019529502A/ja active Pending
- 2017-09-29 TW TW106133810A patent/TWI753952B/zh not_active IP Right Cessation
- 2017-09-29 WO PCT/US2017/054473 patent/WO2018064559A1/en not_active Ceased
-
2019
- 2019-01-16 US US16/249,290 patent/US10973784B2/en not_active Expired - Fee Related
- 2019-03-27 IL IL265656A patent/IL265656A/en unknown
- 2019-03-29 MX MX2021014093A patent/MX2021014093A/es unknown
-
2021
- 2021-03-01 US US17/188,413 patent/US20210177783A1/en not_active Abandoned
- 2021-12-01 AU AU2021277698A patent/AU2021277698A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3037059A1 (en) | 2018-04-05 |
| US20190142771A1 (en) | 2019-05-16 |
| AU2017337053B2 (en) | 2021-09-02 |
| MX2021014093A (es) | 2021-12-10 |
| MX2019003720A (es) | 2019-09-19 |
| WO2018064559A1 (en) | 2018-04-05 |
| US10314798B2 (en) | 2019-06-11 |
| JP2019529502A (ja) | 2019-10-17 |
| AU2021277698A1 (en) | 2021-12-23 |
| EP3518914A4 (en) | 2020-06-10 |
| TW201813638A (zh) | 2018-04-16 |
| US20180092868A1 (en) | 2018-04-05 |
| US20210177783A1 (en) | 2021-06-17 |
| EP3518914A1 (en) | 2019-08-07 |
| IL265656A (en) | 2019-05-30 |
| AU2017337053A1 (en) | 2019-04-04 |
| US10973784B2 (en) | 2021-04-13 |
| TWI753952B (zh) | 2022-02-01 |
| MX387961B (es) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| AR109760A1 (es) | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2022000619A (es) | Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. | |
| AR104427A1 (es) | Composiciones farmacéuticas para terapia de combinación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |